1. Home
  2. VIR vs CPAC Comparison

VIR vs CPAC Comparison

Compare VIR & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • CPAC
  • Stock Information
  • Founded
  • VIR 2016
  • CPAC 1949
  • Country
  • VIR United States
  • CPAC Peru
  • Employees
  • VIR N/A
  • CPAC N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • CPAC Building Materials
  • Sector
  • VIR Health Care
  • CPAC Industrials
  • Exchange
  • VIR Nasdaq
  • CPAC Nasdaq
  • Market Cap
  • VIR 706.4M
  • CPAC 580.5M
  • IPO Year
  • VIR 2019
  • CPAC 2012
  • Fundamental
  • Price
  • VIR $5.08
  • CPAC $6.85
  • Analyst Decision
  • VIR Strong Buy
  • CPAC Hold
  • Analyst Count
  • VIR 10
  • CPAC 1
  • Target Price
  • VIR $26.80
  • CPAC $6.40
  • AVG Volume (30 Days)
  • VIR 1.5M
  • CPAC 4.6K
  • Earning Date
  • VIR 10-30-2025
  • CPAC 10-27-2025
  • Dividend Yield
  • VIR N/A
  • CPAC 7.70%
  • EPS Growth
  • VIR N/A
  • CPAC 26.68
  • EPS
  • VIR N/A
  • CPAC 0.14
  • Revenue
  • VIR $19,000,000.00
  • CPAC $572,828,408.00
  • Revenue This Year
  • VIR N/A
  • CPAC N/A
  • Revenue Next Year
  • VIR $9.65
  • CPAC N/A
  • P/E Ratio
  • VIR N/A
  • CPAC $9.44
  • Revenue Growth
  • VIR N/A
  • CPAC 3.37
  • 52 Week Low
  • VIR $4.16
  • CPAC $5.10
  • 52 Week High
  • VIR $14.45
  • CPAC $6.90
  • Technical
  • Relative Strength Index (RSI)
  • VIR 51.83
  • CPAC 61.50
  • Support Level
  • VIR $5.04
  • CPAC $6.50
  • Resistance Level
  • VIR $5.39
  • CPAC $6.79
  • Average True Range (ATR)
  • VIR 0.34
  • CPAC 0.22
  • MACD
  • VIR 0.05
  • CPAC 0.01
  • Stochastic Oscillator
  • VIR 49.20
  • CPAC 82.71

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About CPAC Cementos Pacasmayo S.A.A. (Each representing five)

Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.

Share on Social Networks: